Lupin Pharma Canada, Endoceutics to partner for commercialisation of Intrarosa
It is indicated for the treatment of postmenopausal vulvovaginal atrophy offered as a vaginal ovule containing 6.5 mg of Prasterone
Lupin Pharma announced a partnership with Endoceutics, a Canadian biotech company, to commercialise Intrarosa in Canada. Intrarosa is Endoceutic’s flagship product indicated for the treatment of postmenopausal vulvovaginal atrophy offered as a vaginal ovule containing 6.5 mg of Prasterone.
Commenting on the partnership, Dr Sofia Mumtaz, President, Lupin Pharma Canada said, “We are very pleased to partner with Endoceutics to bring this long-awaited innovative product to the Canadian market. Intrarosa will not only expand and strengthen our product portfolio into Women’s Health in Canada but will cater to satisfy the unmet medical needs.”
“We are very excited to be working closely with Lupin in Canada. We believe they are the right partner to successfully bring Intrarosa to the market,” commented Dennis Turpin, President and CEO, Endoceutics.